Hirotoshi Iihara

机构：Gifu Pharmaceutical University, Gifu University Hospital · ORCID：0000-0002-4171-454X

发表论文 171 篇 · 总被引 2046 次 · h-index 25

代表论文

Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial (2025 · The Lancet Oncology · 被引 13)
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates (2025 · Future Oncology · 被引 10)
Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions (2025 · Anticancer Research · 被引 10)
Cancer cachexia onset and survival outcomes in metastatic colorectal cancer: Comparative assessment of the asian working group for cachexia and the European palliative care research collaborative criteria, and utility of modified glasgow prognostic score (2025 · International Journal of Colorectal Disease · 被引 6)
Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team (2025 · International Journal of Clinical Oncology · 被引 5)
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology (2024 · International Journal of Clinical Oncology · 被引 5)